Why Did GSK Pay $1.9B for Momelotinib, an Oral Ph. III Myelofibrosis Candidate?
Momelotinib, an oral JAK1/2 inhibitor for myelofibrosis, is going to GSK as part of a $1.9 billion acquisition of Sierra Oncology. Anyone that’s ever worked on a kinase program probably looked at this structure and raised their eyebrows. $1.9 billion for another JAK2 inhibitor? It’s probably not super selective either, you might think… and you’d…
Top Small Molecule M&A Transactions in 2021
What were the billion-dollar small molecules in 2021? This article and infographic, which is part 3 of a Premium series covering 2021 drug discovery M&A, covers: The ten largest drug discovery biotech acquisitions by total consideration in 2021 where the acquiree’s lead was a small molecule The lead molecules in each acquisition and their structural…
Top Large Molecule M&A Transactions in 2021
What were the billion-dollar large molecules in 2021? This article and infographic, which is part 4 of a Premium series covering 2021 drug discovery M&A, covers:
Drug Discovery M&A Upfront Payments in 2021
This article and infographic highlights the drug discovery biotech acquisitions of 2021 where the upfront payment was disclosed, along with the structures of lead molecules in each acquisition where disclosed, mechanism of action, development stage, and indication. You can find Part I here.
Top 10 Drug Discovery Biotech M&A Transactions of 2021 by Overall Value
We reviewed all of the biotech mergers and acquisitions announced in 2021 and did a deep dive on the list of biotech M&A transactions focused on drug discovery. The infographic below, which is part 1 of a Premium series covering 2021 drug discovery M&A, covers: The top ten overall small or large molecule drug acquisitions…
Sisunatovir, Oral Ph. II RSV Candidate, to Be Acquired by Pfizer
It’s always nice to see a small molecule making the front page of the news, especially when it’s a Molecule of the Month from last year! Pfizer and ReViral announced an agreement for Pfizer to acquire ReViral for up to $525 million, including milestones (amount upfront not disclosed). ReViral’s lead molecule sisunatovir, is an oral,…